Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration

Current Neuropharmacology

Volumn 8, Issue 1, 2010, Pages 62-68

  Bartels, Anna L ^a   Leenders, Klaus L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

COX 2; Microglia; Neurodegeneration; Neuroinflammation; Neuroprotection; Parkinson

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

BRAIN DEGENERATION; ENCEPHALITIS; ENZYME ACTIVITY; HUMAN; MICROGLIA; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW;

EID: 77950249229     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015910790909485     Document Type: Review

References (63)

1. Aid, S., Langenbach, R., Bosetti, F. (2008) Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J. Neuroinflam., 5, 17.
2. Bartels, A.L, Willemsen, A.T., Doorduin, J., de Vries, E.F., Dierckx, R.A., Leenders K.L. (2009) [(11)C]-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat., Disord. 6, 57-59
3. Bartels, A.L., Willemsen, A.T., Kortekaas, R., de Jong, B.M., de V.R., de K.O., van Oostrom, J.C., Portman, A., Leenders, K.L. (2008) Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural. Transm., 115, 1001-1009
4. Bauer, B., Hartz, A.M., Pekcec, A., Toellner, K., Miller, D.S., Potschka, H. (2008) Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol., 73,1444-1453.
5. Beach, T.G., Sue, L.I., Walker, D.G., Lue, L.F., Connor, D.J., Caviness, J.N., Sabbagh, M.N., Adler, C.H. (2007) Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol., 114, 419-424.
6. Bezzi, P., Domercq, M., Brambilla, L., Galli, R., Schols, D., De Clercq, E., Vescovi ,A., Bagetta, G., Kollias, G., Meldolesi, J., Volterra, A. (2001) CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci., 4, 702-710.
7. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K., Schnitzer, T.J. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 343, 1520-1528
8. Boutin, H., Chauveau, F., Thominiaux, C., Gregoire, M.C., James, M.L., Trebossen, R., Hantraye, P., Dolle, F., Tavitian, B., Kassiou, M. (2007) 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J. Nucl. Med., 48,573-581.
9. Boutin, H., Chauveau, F., Thominiaux, C., Kuhnast, B., Gregoire, M.C., Jan, S., Trebossen, R., Dolle, F., Tavitian, B., Mattner, F., Katsifis, A. (2007) In vivo imaging of brain lesions with [(11)C] CLINME, a new PET radioligand of peripheral benzodiazepine receptors. Glia 55, 1459-1468.
10. Bower, J.H., Maraganore, D.M., Peterson, B.J., Ahlskog, J.E., Rocca, W.A. (2006) Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology, 67, 494-496.
11. Braak, H., Braak, E. Pathoanatomy of Parkinson's disease. (2000) J. Neurol., 247, 3-10.
12. Breder, C.D., Dewitt, D., Kraig, R.P. (1995) Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol., 355, 296-315.
13. Carrasco, E., Casper, D., Werner, P. (2005) Dopaminergic neurotoxicity by 6-OHDA and MPP+: Differential requirement for neuronal cyclooxygenase activity. J. Neurosci. Res., 81, 121-131.
14. Chae, S.W., Kang, B.Y., Hwang, O., Choi , H.J. (2008) Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells. Neurosci. Lett., 436, 205-209.
15. Chandrasekharan, N.V., Dai, H., Roos, K.L., Evanson, N.K., Tomsik, J., Elton, T.S., Simmons, D.L. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U.S.A., 99, 13926-13931.
16. Chen, H., Jacobs, E., Schwarzschild, M.A., McCullough, M.L., Calle, E.E., Thun, M.J., Ascherio, A. (2005) Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol., 58, 963-967.
17. Chen, H.L., Zhang, S.M.M., Hernan, M.A., Schwarzschild, M.A., Willett, W.C., Colditz, G.A., Speizer, F.E., Ascherio, A. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol., 60, 1059-1064.
18. Choi, S.H., Aid, S., Bosetti, F. (2009) The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol. Sci., 30, 174-181.
19. Colville-Nash, P.R., Gilroy, D.W. (2001) Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. Bio. Drugs, 15, 1-9.
20. De Simone, R., Ajmone-Cat, M.A., Minghetti , L. (2004) Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction. Mol. Neurobiol.,29, 197-212.
21. de Vries E.F., Doorduin, J., Vellinga, N.A., van Waarde, A., Dierckx, R.A., Klein, H.C. (2008) Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl. Med. Biol., 35, 459-466.
22. Dehmer, T., Heneka, M.T., Sastre, M., Dichgans, J., Schulz, J.B. (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem., 88, 494-501.
23. Doorduin, J., Klein, H.C., Dierckx, R.A., James, M., Kassiou, M., de Vries, E.F. (2009) [(11)C]-DPA-713 and [(18)F]-DPA-714 as New PET tracers for TSPO: A comparison with [(11)C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis. Mol. Imaging Biol., 11, 586-598
24. Etminan, M., Carleton, B.C., Samii, A. (2008) Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J. Clin. Neurosci., 15, 576-577.
25. Etminan, M., Suissa, S: NSAID use and the risk of Parkinson's disease. (2006) Curr. Drug Saf., 1, 223-225.
26. Feng, Z.H., Wang, T.G., Li, D.D., Fung, P., Wilson, B.C., Liu, B., Ali, S.F., Langenbach, R., Hong, J.S. (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett., 329, 354-358.
27. Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R.B., Brooks, D.J. (2006) In vivo imaging of microglial activation with [C-11](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis., 21, 404-412.
28. Hancock, D.B., Martin, E.R., Stajich, J.M., Jewett, R., Stacy, M.A., Scott, B.L., Vance, J.M., Scott, W.K. (2007) Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch. Neurol., 64, 576-580.
29. Hernan, M.A., Logroscino, G., Garcia, Rodriguez, L.A. (2006) Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology, 66, 1097-1099.
30. Hunter, R.L., Dragicevic, N., Seifert, K., Choi, D.Y., Liu, M., Kim, H.C., Cass, W.A., Sullivan, P.G., Bing, G. (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem., 100, 1375-1386.
31. Imaizumi, M., Briard, E., Zoghbi, S.S., Gourley, J.P., Hong, J., Fujimura, Y., Pike, V.W., Innis, R.B., Fujita, M. (2008) Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage, 39,1289-1298.
32. Jenner, P., Olanow, C.W. (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 47, S161-S170.
33. Jones, S.C. (2005) Relative thromboembolic risks associated with COX-2 inhibitors. Ann. Pharmacother., 39, 1249-1259.
34. Kaufmann, W.E., Worley, P.F., Pegg, J., Bremer, M., Isakson, P. (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U.S.A., 93, 2317-2321.
35. Knott, C., Stern, G., Wilkin, G.P. (2000) Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell Neurosci., 16, 724-739.
36. Kunz, A., Anrather, J., Zhou, P., Orio, M., Iadecola, C. (2007) Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J. Cereb. Blood Flow Metab., 27,545-551.
37. McCullough, L., Wu, L., Haughey, N., Liang, X., Hand, T., Wang, Q., Breyer, R.M., Andreasson, K. (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci., 24, 257-268.
38. Mcgeer, P.L., Itagaki, S., Boyes, B.E., Mcgeer, E.G. (1988) Reactive Microglia Are Positive for Hla-Dr in the Substantia Nigra of Parkinsons and Alzheimers-Disease Brains. Neurology, 38, 1285-1291.
39. Minghetti, L. (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol., 63, 901-910.
40. Minghetti, L., Ajmone-Cat, M.A., De Berardinis, M.A., De Simone, R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res. Brain Res. Rev., 48, 251-256.
41. Mirza, B., Hadberg, H., Thomsen, P., Moos, T. (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience, 95, 425-432.
42. Niwa, K., Araki, E., Morham, S.G., Ross, M.E., Iadecola, C. (2000) Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci., 20, 763-770.
43. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., Torizuka, T. ( 2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol., 57, 168-175.
44. Rohn, T.T., Wong, S.M., Cotman, C.W., Cribbs, D.H. (2004) 15-deoxy-delta12, 14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis. Neuroreport, 12, 839-843.
45. Sanchez-Pernaute, R., Ferree, A., Cooper, O., Yu, M., Brownell, A.L., Isacson, O. (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation, 1, 6.
46. Shaftel, S.S., Olschowka, J.A., Hurley, S.D., Moore, A.H., O'Banion, M.K. (2003) COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res. Mol. Brain Res.,119, 213-215.
47. Shaw, K.N., Commins, S., O'Mara, S.M. (2003) Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad-spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain-derived neurotrophic factor. Eur. J. Neurosci., 17, 2438-2446.
48. Silverstein, F.E., Faich, G., Goldstein, J.L., Simon, L.S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N.M., Stenson, W.F., Burr, A.M., Zhao, W.W., Kent , J.D., Lefkowith, J.B., Verburg, K.M., Geis, G.S. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 284, 1247-1255.
49. Smith, W.L., Dewitt, D.L., Garavito, R.M. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem., 69,145-182.
50. Sriram, K., Miller, D. B., O'Callaghan, J.P. (2006) Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem., 96, 706-718.
51. Sugama, S., Yang, L., Cho, B.P., DeGiorgio, L.A., Lorenzl, S., Albers, D.S., Beal , M.F., Volpe, B.T., Joh, T.H. (2003) Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res., 964, 288-294.
52. Teather, L.A., Packard, M.G., Bazan, N.G. (2002) Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn Mem., 9, 41-47.
53. Teismann, P., Tieu, K., Choi, D.K., Wu, D.C., Naini, A., Hunot, S., Vila, M., Jackson-Lewis, V., Przedborski, S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl.Acad. Sci. U.S .A., 100, 5473-5478.
54. Teismann, P., Tieu, K., Cohen, O., Choi, D.K., Wu, D.C., Marks, D., Vila, M., Jackson-Lewis, V., Przedborski, S. (2003)Pathogenic role of glial cells in Parkinson's disease. Mov.Disord., 18, 121-129.
55. Ton, T.G., Heckbert, S.R., Longstreth, W.T., Jr., Rossing, M.A., Kukull, W.A., Franklin, G.M., Swanson, P.D., Smith-Weller, T., Checkoway, H. (2006) Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord., 21, 964-969.
56. Venneti, S., Wang, G., Wiley, C.A. (2008)The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds to activated and infected brain macrophages in areas of synaptic degeneration: implications for PET imaging of neuroinflammation in lentiviral encephalitis. Neurobiol. Dis.,29, 232-241.
57. Vijitruth, R., Liu, M., Choi, D.Y., Nguyen, X.V., Hunter, R.L., Bing, G. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation, 3, 6.
58. Vogelgesang, S., Cascorbi, I., Kroemer, H.K., Schroeder, E., Pahnke, J., Siegmund, W., Keil, C., Warzok, R.W., Walker, L.C. (2001) Deposition of amyloid is inversely correlated with the expression of p-glycoprotein - implications on the possibility of prevention of Alzheimer's disease. Acta Neuropathologica, 102, 545.
59. Wahner, A.D., Bronstein, J.M., Bordelon, Y.M., Ritz, B. (2007) Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology, 69, 1836-1842.
60. Wang, T.G., Pei, Z., Zhang, W., Liu, B., Langenbach, R., Lee, C., Wilson, B., Reece, J.M., Miller, D.S., Hong , J.S. (2005) MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J., 19, 1134-1136.
61. Willoughby, D.A., Moore, A.R., Colville-Nash, P.R. (2000) Cyclopentenone prostaglandins-new allies in the war on inflammation. Nat. Med., 6, 137-138.
62. Yamagata, K., Andreasson, K.I., Kaufmann, W. E., Barnes, C.A., Worley, P.F. (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 11, 371-386.
63. Yasojima, K., Schwab, C., Mcgeer, E.G., Mcgeer, P.L. (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res., 830, 226-236.